Xcovery Inc. launched the phase III trial of X-396 (ensartinib), its lead ALK inhibitor, as a first-line treatment in patients with ALK+ non-small-cell lung cancer. The global, open-label, randomized eXalt3 study is expected to enroll approximately 400 patients to evaluate the efficacy and safety of X-396 head-to-head against Pfizer Inc.'s Xalkori (crizotinib).